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Abstract
Background: Silver-Russell syndrome (SRS) is a genetically and clinically heterogeneous disease. Although no protein
coding gene defects have been reported in SRS patients, approximately 50% of SRS patients carry epimutations
(hypomethylation) at the IGF2/H19 imprinting control region 1 (ICR1). Proper methylation at ICR1 is crucial for the imprinted
expression of IGF2, a fetal growth factor. CTCFL, a testis-specific protein, has recently been proposed to play a role in the
establishment of DNA methylation at the murine equivalent of ICR1. A screen was undertaken to assess whether CTCFL is
mutated in SRS patients with hypomethylation, to explore a link between the observed epimutations and a genetic cause of
the disease.
Methodology/Principal Findings: DNA was obtained from 36 SRS patients with hypomethylation at ICR1. All CTCFL coding
exons were sequenced and analyzed for duplications/deletions using both multiplex ligation-dependent probe
amplification, with a custom CTCFL probe set, and genomic qPCR. Novel SNP alleles were analyzed for potential differential
splicing in vitro utilizing a splicing assay. Neither mutations of CTCFL nor duplications/deletions were observed. Five novel
SNPs were identified and have been submitted to dbSNP. In silico splice prediction suggested one novel SNP, IVS2-66A.C,
activated a cryptic splice site, resulting in aberrant splicing and premature termination. In vitro splicing assays did not
confirm predicted aberrant splicing.
Conclusions/Significance: As no mutations were detected at CTCFL in the patients examined, we conclude that genetic
alterations of CTCFL are not responsible for the SRS hypomethylation. We suggest that analysis of other genes involved in
the establishment of DNA methylation at imprinted genes, such as DNMT3A and DNMT3L, may provide insight into the
genetic cause of hypomethylation in SRS patients.
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Introduction
Silver-Russell syndrome (SRS) is a rare and genetically
heterogeneous disease (OMIM: 180860). Diagnosis of SRS
includes: low birth weight and height, poor postnatal growth,
skeletal asymmetry, triangular facial features and distinct head
shape [1]. The etiology of the disease remains elusive as no protein
coding gene mutations have been identified, although maternal
uniparental disomy of chromosome 7 is observed in ,10% of SRS
patients [1]. More recently, however, an epimutation, hypomethy-
lation of the IGF2/H19 imprinting control region 1 (ICR1) at
11p15, was observed in SRS patients and is now reported in
approximately 50% of cases [1,2]. Moreover, the extent of
hypomethylation at ICR1 has recently been correlated to the
severity of the disease [3,4].
Methylation of the paternal ICR1 is crucial for imprinted
expression of the two adjacent genes, IGF2 and H19. IGF2 codes
for a fetal growth factor and is expressed uniquely from the
paternal allele, while H19, a non-coding RNA, is expressed solely
from the maternal allele [5,6]. ICR1 is unmethylated on the
maternal allele which allows binding by the insulator protein
CTCF. CTCF blocks enhancer access to the IGF2 promoter,
resulting in the silencing of IGF2 on the maternal allele [7].
However, methylation of the paternal ICR1 abrogates CTCF
binding and IGF2 expression is activated [8,9]. Diminished IGF2
expression, through ICR1 hypomethylation and subsequent
CTCF binding and IGF2 enhancer blocking on the paternal
allele, is thought to be responsible for the low birth weight and
poor post-natal growth observed in SRS patients. Therefore, the
ICR1 hypomethylation epimutation provides the strongest insight
into the genetic cause of SRS and suggests that gene products
involved in the establishment of DNA methylation at ICR1 may
be mutated in SRS patients with hypomethylation.
A mechanism for the establishment of DNA methylation at
murine imprinted genes has recently been proposed involving the
protein CTCFL/BORIS [10]. CTCF-like (CTCFL) or Brother Of
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CTCFL, and the ubiquitously expressed CTCF are closely related
by 79% similarity among the 11 zinc fingers they both contain
[11]. However, CTCFL is uniquely expressed in the testis and
shares no significant similarity in either the N- or C-termini to
CTCF, suggesting that the two proteins perform different
functions, although they most likely bind similar DNA sites [11].
Our laboratory has shown that CTCFL binds the murine
equivalent of ICR1, the Igf2/H19 ICR, in vivo and interacts with
the arginine methyltransferase PRMT7 and histones H1, H2A
and H3. PRMT7 methylates histones H2A and H4 and CTCFL
stimulates PRMT7-mediated histone methylation. Additionally,
when CTCFL is expressed in Xenopus oocytes, with PRMT7 and
the de novo DNA methyltransferases 3A, 3B and L (DNMT3A, B,
L), which are essential for the establishment of methylation at
imprinted genes [12–14], CpG dinucleotides of a plasmid
containing murine ICR1 are methylated [10]. The current model
contends that CTCFL specifically binds the Igf2/H19 ICR,
recruits PRMT7, which then methylates nearby histones. This
histone methylation can then serve as a recruitment signal for the
de novo DNA methyltransferases which methylate the CpGs of the
Igf2/H19 ICR. Recently, DNMT3A recruitment mediated by
PRMT5 histone arginine methylation has been demonstrated,
consistent with the proposed model [15].
Based on observations of hypomethylation at ICR1 in SRS
patients and the proposed role of CTCFL in directing DNA
methylation at the Igf2/H19 ICR, we hypothesized that SRS
patients with hypomethylation at ICR1 could potentially harbor
mutations in CTCFL, which would provide a genetic link to the
epimutations observed in these patients. To test this hypothesis, 36
SRS patients with hypomethylation at ICR1 were screened for
mutations in CTCFL. Additionally, the SRS patients were screened
for exonic duplications/deletions using multiplex ligation-depen-
dent probe amplification (MLPA) and qPCR. Lastly, a novel SNP
revealed by CTCFL sequencing, and predicted in silico to activate a
cryptic splice site, was tested for possible alternative splicing.
Results
Sequence analysis
CTCFL consists of 10 coding exons and 3 alternative first exons,
which will be denoted here as the 59UTR (Figure 1A) [11,16]. All
coding exons and the 59UTR of CTCFL were sequenced in 36
SRS patients with hypomethylation at ICR1. Sequencing revealed
SNPs present in dbSNP and included 5 polymorphic HapMap
SNPs (Figure 1A). The HapMap SNPs allele frequencies did not
significantly differ between SRS patients and the CEU population
(Table 1). Five novel SNPs (not listed in either dbSNP or ABI SNP
Figure 1. Distribution of polymorphic HapMap and novel SNPs within CTCFL. A) CTCFL gene structure showing relative positions of exons
(solid boxes) and 59UTR (dashed box). Sequencing of SRS patient DNAs led to the detection of novel SNPs (red dashes) and polymorphic HapMap
SNPs (green dashes). B) Representative chromatograms of novel SNPs in comparison to wild-type sequence.
doi:10.1371/journal.pone.0006631.g001
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(Figure 1A, 1B), but the frequency of the observed SNPs did not
significantly differ between the patients and healthy controls
(Table 2). All novel SNPs have been deposited in dbSNP (Table 2).
No nonsense or missense mutations were found in any of the
patients, but one heterozygous silent mutation (1562A.G; K.K)
was observed in exon 9 of one patient (Figure 1B).
Exon duplication/deletion analysis
CTCFL was also screened for exonic deletions or duplications in
these same patients using MLPA. Custom oligonucleotide MLPA
probes were designed for each exon (Table S2). Twenty-one
patients were screened at exons 2–11 and normalized by
comparison to 7 healthy controls. Two SRS patients had a
normalized value of 0.6 for exon 9 of CTCFL, suggesting a possible
deletion (Figure 2A). To further examine exon 9 deletion in these
patients, genomic qPCR was performed. CTCFL exon 9 was
amplified in 27 patients and compared to levels of a diploid
control, TP53 (Figure 2B). Also, as a second control, qPCR was
performed on the X chromosome gene STS which is single copy in
males. No patient had a quantity of exon 9 as low as the male
patients at the STS locus (Figure 2B). Moreover, the copy number
of CTCFL exon 9 for patients with the possible deletion was not
significantly different from TP53 (Figure 2B), suggesting that exon
9o fCTCFL is not deleted in these patients.
MLPA also indicated a possible duplication of exon 5 in two
patients with normalized ratios at or above 1.4 (Figure 2A).
Extensive PCR analysis of exon 5 and the surrounding genomic
region did not provide supporting evidence for exon 5 duplication
(Figure 3).
Splicing analysis
As four of the five novel SNPs were observed in introns, analysis
was undertaken to determine if these novel SNPs could affect
splicing of CTCFL. In silico prediction of splicing using sequence
from both the wild-type and novel SNPs was performed using two
online tools, Flybase Splice Site Predictor and ESE Finder. All
novel SNPs were tested, but only one SNP, IVS2-66A.C, was
predicted by both programs to activate an alternative 39 splice site
four nucleotides downstream from the SNP itself and to
consequently add 61 bps to exon 3 resulting in a frame-shift and
premature termination (Figure 4A). Testis samples from the SRS
Table 1. Polymorphic HapMap SNPs at CTCFL in SRS patients and CEU population.
Exon Genotype Frequency in SRS Patients Hapmap Frequency (CEU) dbSNP ID
2( 5 9) C/C 18 (50%) 30.0% rs6070128
C/G 12 (33.3%) 56.7%
G/G 6 (16.7%) 13.3%
2( 3 9) C/C 10 (27.8%) 38.3% rs6025606
C/T 18 (50%) 51.7%
T/T 8 (22.2%) 10%
6 A/A 26 (72.2%) 72.4% rs6025601
A/G 10 (27.8%) 24.1%
G/G 0 (0%) 3.4%
9 G/G 35 (97.2%) 90% rs6070122
G/C 1 (2.8%) 10%
10 G/G 20 (55.6%) 51.7% rs6128059
G/A 13 (36.1%) 41.7%
A/A 3 (8.3%) 6.6%
doi:10.1371/journal.pone.0006631.t001
Table 2. Novel SNPs and frequencies in SRS patients and healthy controls at CTCFL.
SNP Genotypes Frequency in patients Frequency in controls dbSNP ID
-775T.A T/T 20 (87%) 42 (97.7%) ss115492397
T/A 3 (13%) 1 (2.3%)
-614delT T/T 21 (91.3%) 41 (91.1%) ss115492398
del/T 2 (8.7%) 4 (8.9%)
IVS2+55G.A G/G 35 (97.2%) 95 (100%) ss115492399
G/A 1 (2.8%) 0
IVS2-66A.C A/A 32 (88.9%) 95 (95%) ss115492400
A/C 4 (11.1%) 5 (5%)
1562A.G A/A 35 (97.2%) 95 (100%) ss115492401
A/G 1 (2.8%) 0
doi:10.1371/journal.pone.0006631.t002
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[10,11]. We therefore analyzed splicing among IVS2-66A.C and
other nearby SNPs using a minigene splicing assay [17]. Total
RNA was extracted from 293T cells transfected with a minigene
plasmid (pRHCglo E2-5) containing the genomic region encom-
passing exons 2–5 of CTCFL with alleles carrying either the wild-
type or variant SNP at IVS2-66. As other SNPs are located in the
genomic region contained in pRHCglo E2-5, these were also
tested for possible differential splicing. These SNPs included: two
HapMap SNPs (rs6070128 and rs6025606), one other novel SNP
(IVS2+55G.A) and a previously observed non-HapMap SNP
(rs11699220) (Figure 4B). After specific reverse transcription and
PCR of the spliced minigene transcript, no differences in splicing
were observed for any of the alleles tested (Figure 4B).
Discussion
All CTCFL exons were sequenced in SRS patients to test the
hypothesis that mutations in this gene may be responsible for
hypomethylation of ICR1. No missense or nonsense mutations
were found. However, five novel SNPs were identified. As one of
the novel SNPs (IVS2-66A.C) was predicted to activate a cryptic
39 splice site near exon 3, a minigene splicing assay was used to
determine if CTCFL undergoes SNP-dependent alternative
splicing. Neither IVS2-66A.C nor alleles of nearby SNPs
displayed alternative splicing at the exon 2/3 junction. These
results rule out splicing aberrations of CTCFL as a cause of
hypomethylation in these patients. Lastly, the exons of CTCFL in
SRS patients were screened for duplications/deletions using
MLPA and qPCR. No duplications/deletions were observed,
strongly suggesting that genetic alterations of CTCFL are not
present in these patients.
As maternal uniparental disomy of chromosome 7 is observed in
,10% of SRS patients[1], previous SRS candidate gene studies
have focused on chromosome 7 [18–24]. To our knowledge, this
study is the first candidate gene approach to examine genes
involved in the establishment of imprinted DNA methylation at
ICR1. Our findings in this cohort of SRS patients do not indicate
that mutations in CTCFL are a cause of the hypomethylation
epimutation. If CTCFL participates in directing global imprinted
gene DNA methylation as proposed [10], a mutation in the gene
may lead to either an embryonic lethal or more severe phenotype
than SRS. This is but one explanation for the absence of observed
CTCFL alterations in SRS patients. Future investigation will clarify
the full impact of CTCFL function on the establishment of DNA
methylation during development.
Further investigation may also point to mutations in other
genes/proteins participating in the establishment of DNA
methylation at imprinted genes as a cause of hypomethylation in
these patients. The de novo DNA methyltransferases DNMT3A and
DNMT3L have been shown to be essential for normal imprinted
DNA methylation [12,13] and make strong candidates for a
mutational screen in SRS patients with hypomethylation of ICR1
[25]. Lastly, a more comprehensive understanding of the
mechanism of de novo DNA methylation at imprinted genes may
provide novel candidate genes for further study into the cause of
the hypomethylation epimutation and SRS.
Materials and Methods
Ethics Statement
The study was performed in accordance with the ethics review
boards of the University of Zu ¨rich, University of Lausanne and the
University Hospital of Lausanne (CHUV). Written informed
consent for analysis of DNA was obtained from all adult patients
and parents of underage patients included in this work.
Patients
The study population consisted of a 36 patient subgroup from a
pool of 201 SRS patients diagnosed by clinics in Zu ¨rich, Warsaw,
Minsk, and Istanbul. These 36 patients were selected for further
analysis due to hypomethylation at the IGF2/H19 ICR as
determined by methylation-specific MLPA [3]. The 36 patients
have SRS severity scores ranging from 8 to 15 (mean, 11.8, 4
undetermined) as ascertained by Bartholdi et al [3]. One hundred
Figure 2. CTCFL exon duplication/deletion analysis in SRS
patients. A) MLPA analysis of CTCFL exons in SRS patient DNA.
Connected symbols represent individual patients. Values obtained
relative to control samples are presented. B) Copy number analysis of
CTCFL exon 9 by genomic qPCR. Each point represents the mean Ct for
the given reaction, normalized by the mean Ct obtained for TP53
(autosomal, two copies) from the same sample. All reactions were
performed in quadruplicate and error bars represent standard error
from the mean. All samples use FC (female control, non-SRS) as the
reference sample. Numbers 19–213 refer to SRS patients and MC
represents the male control (non-SRS).
doi:10.1371/journal.pone.0006631.g002
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was extracted as previously described [3].
Sequencing
CTCFL genomic sequence was downloaded from NCBI Map
Viewer and exons were demarcated using the NCBI cDNA
sequence NM_080618.2. SNPs were identified using dbSNP and
the ABI GeneAssist Genotyping Alignment Map (Applied
Biosystems website). This map was then used to design intronic
primers to individually amplify exons 2–11 and nested or partially
nested primers sequencing primers to directly sequence the PCR
products (Table S1). 59UTR PCR primers were designed to
encompass the entire 59UTR as described by Renaud et al. [16]
100 ng of genomic DNA was used in 50 ml PCR reactions for each
exon in each patient using either AmpliTaq Gold (ABI, exons 2–
11) or Phusion DNA Polymerase (Finnzymes, 59UTR). PCR
reaction conditions are available upon request. After purification
with the QIAquick PCR Purification Kit (Qiagen), PCR products
were sequenced and run on an ABI 3130xl DNA Fragment
Analyzer. Chromatograms were manually inspected using
FinchTV (Geospiza).
MLPA
MLPA reactions were performed using the SALSA MLPA kit
(MRC-Holland, Amsterdam, Netherlands) according to manufac-
turer’s instructions. Briefly, 100 ng of genomic DNA was
denatured for 5 min. at 98uC and cooled to 25uC. A master mix
containing the CTCFL probemix (Table S2), DQ- and DD-control
probes (MRC-Holland) and MLPA buffer were added and the
mixture was heated briefly (1 min.) to 95uC, before annealing the
MLPA probes to the genomic DNA at 60uC overnight. A
mastermix containing Ligase-65 Buffers A+B and Ligase-65 was
added to the same tubes at 54uC and allowed to ligate for 15 min.
followed by a 5 min. incubation at 98uC and stored at 4uC. 50 ml
PCR reactions were performed using 10 ml of MLPA reaction
product with SALSA PCR primers (FAM-labeled), enzyme
Figure 3. PCR analysis of exon 5 duplication. MLPA analysis suggested exon 5 duplication in SRS patient 162. Ten separate PCR reactions were
performed to analyze exon 5 and adjacent genomic regions for evidence of duplication (scheme shown on top). PCR products from the respective
reactions are shown for both patient 162 (left lane) and control (right lane) DNA. The sequences of primers used are given in Table S4.
doi:10.1371/journal.pone.0006631.g003
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of SNPs indicated. The sequences and scores are outputs from the FlyBase Splice Prediction program. Higher scores indicate better alignment of the
sequence to known splice sites. Arrows mark the nucleotide position changed by IVS2-66A.C and the score at the cryptic splice site increases from
0.66 to 0.94 with the single nucleotide substitution. Also shown is the wild-type CTCFL splicing according to the demarcated exon/intron junctions.
Splicing for the IVS2-66A.C substitution is predicted to splice exon 2 to a cryptic splice site 61 bp upstream of the wild-type 59exon 3 splice site
(shown on bottom with the associated FlyBase score). Mis-splicing predicts a frame shift and premature termination in exon 3. B) The genomic region
cloned into pRHCglo is shown and the relative positions of the SNPs analyzed are denoted a-e. The table shows the haplotypes for each minigene
cloned into pRHCglo which were derived from both SRS patient and control DNA. Each pRHCglo E2-5 plasmid was transfected into 293T cells, the
RNA extracted and reverse transcribed. PCR products were run on an agarose gel and visualized with ethidium bromide. No alternative splice
products were observed.
doi:10.1371/journal.pone.0006631.g004
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cycling conditions. The FAM-labeled PCR products were
separated on an ABI 3130xl and the size was determined by the
addition of ROX-250-labelled size standards (ABI). The MLPA
PCR products were visualized with Peakscanner software (ABI)
and quality-checked by the presence/absence of DQ- and DD-
control fragments. The chromatograms were exported as .fsa files
to Coffalyser (MRC-Holland) for statistical analysis. Chromato-
grams of 7 healthy controls were used to normalize those of SRS
patients.
qPCR
Genomic DNA from SRS patients and healthy controls was
used for quantitative real-time PCR (qPCR) to screen for deletions
at exon 8 and 9 of CTCFL. Primers were designed for exons 8 and
9o fCTCFL, exon 7 of TP53 (diploid control) and exon 5 of steryl-
sulfatase precursor (STS), an X chromosome gene (haploid control,
in males) (Table S3).
This allowed normalization of all reactions to TP53, while
facilitating analysis of possible deleted CTCFL exons by compar-
ison to STS reactions in males, which have only one copy of the
gene. The concentration for each primer pair was optimized for
10 ml reactions and was used as follows: CTCFL exon 8 200 nM,
CTCFL exon 9 400 nM, TP53 200 nM, STS 600 nM. Reactions
were performed using 50 ng of genomic DNA with 2X Power
SYBRH Green PCR Master Mix (ABI), forward and reverse
primer mix (5 mM) and water to 10 ml. All qPCR reactions were
run on an ABI 7900HT using standard conditions.
Minigene splicing assay
To analyze possible mis-splicng caused by novel SNPs in
CTCFL we first used in silico methods to search for possible splice-
altering SNPs. Two online programs, Flybase Splice Site Predictor
(http://www.fruitfly.org:9005/seq_tools/splice.html)[26] and ESE
Finder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi)[27] were used to analyze splice sites with or without the novel
SNP and flanking sequence. To experimentally test for alternative
splicing caused by novel SNPs we used a minigene splicing assay.
100 ng of patient or control DNA was used in PCR reactions with
Phusion DNA polymerase to amplify the genomic region of CTCFL
encompassing exons 2–5 (E2-5) using primers upstream of exon 2
(miniE2-5f: 59- GCGGGATCCAGAGTGTGCTCAGGCGGA-
AC)anddownstreamofexon5(miniE2-5r:59-CGCACTAGTGT-
GAGTACCGCCAAACCTGTTAG). The PCR product was then
digested with BamHI and SpeI, gel-purified, and cloned into
pRHCglo [17]. Individual colonies of DH10 transformed with
pRHCglo E2-5 were picked, grown overnight and plasmid DNA
was extracted using the QIAprep Spin Miniprep Kit (Qiagen).
Plasmid DNA was sequenced to identify transformants of each
allele. Next, 5 mg of pRHCglo E2-5 plasmid DNA was CaPO4-
tranfected into 293T cells [28]. Cells were grown overnight, the
media was changed the next morning and cells were left to grow for
a total of 48 hours. Total RNA was extracted using TRI-Reagent
(Sigma) and reverse transcription and PCR were performed using
the SuperScript III One-Step RT-PCR System (Invitrogen). The
primer TNIE4 (59-AGGTGCTGCCGCCGGGCGGTGGCTG)
wasused forreverse transcriptionasdescribedbySingh and Cooper
[17]. PCR primers were designed and used to amplify the exon 2/3
boundary to evaluate splicing (splchkf: 59- GTGTGGCCATTAG-
TATCCAG; splchkr: 59- GCTGTAGGTTGATCCTCTTG).
PCR products were then analyzed by agarose gel electrophoresis.
Supporting Information
Table S1 Genomic CTCFL PCR and sequencing primers
Found at: doi:10.1371/journal.pone.0006631.s001 (0.06 MB
DOC)
Table S2 CTCFL MLPA Probes
Found at: doi:10.1371/journal.pone.0006631.s002 (0.04 MB
DOC)
Table S3 qPCR primers
Found at: doi:10.1371/journal.pone.0006631.s003 (0.03 MB
DOC)
Table S4 Exon 5 duplication PCR primers
Found at: doi:10.1371/journal.pone.0006631.s004 (0.03 MB
DOC)
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